3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
21
Gynecologic
7
Gastrointestinal
4
Sarcoma
2
Genitourinary
2
Thoracic
1
Head & Neck
1
Dermatologic
1
Conditions
Melanoma
3
Uveal Melanoma
1
Urologic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Interventions
pembrolizumab
21
Cyclophosphamide
18
fludarabine
8
Radiotherapy
8
Radiosurgery
7
Nivolumab
7
poly ICLC
6
fludarabine phosphate
6
aldesleukin
6
Therapeutics
6
Paclitaxel
6
Magnetic Resonance Spectroscopy
6
durvalumab
5
Psychiatric Rehabilitation
5
Interleukin-2
5
Drug Therapy
5
Docetaxel
5
Cisplatin
5
temsirolimus
4
cemiplimab
4
Trastuzumab
4
Temozolomide
4
Sirolimus
4
Gemcitabine
4
Flow Cytometry
4
Filgrastim
4
Carboplatin
4
tremelimumab
3
technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran
3
pazopanib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
niraparib
×
Dermatologic
×
Clear all
NCT05169437
2025-10-29
PAVO
Tempus AI
Phase 2
Terminated
22 enrolled
17 charts